"Pharmaceutical headline Jun" Furen Pharmaceuticals financial fraud was fined Zhu Wenchen 10 years of market ban

(2020/10/28) Novart Q3 China performance increased by 13%! Sky-high cumulative global sales of gene therapy exceeded $1 billion, Xindili single-resistance sales in the third quarter broke 600 million Ida Bio 2020 happy news, East China Pharmaceuticals acquired a 20% stake in Swiss uric acid enterprises plus code medical beauty field layout ... (Click on the title, can obtain the original text) "Pharmaceutical 1st time" Furen Pharmaceutical financial fraud was fined 5.9 million yuan Real controller Zhu Wenchen 10 years market ban yesterday (October 27), Furen Pharmaceuticals announced that the company received the CSRC issued the "Administrative Penalty Decision" and "Market Ban Decision."
documents show that Furen Pharmaceuticals' performance has been false for years, and the company and related personnel have been fined a total of 5.9 million yuan.
, zhu Wenchen, the company's real controller, has been banned from the securities market for 10 years.
headlines: because of a "dividend" caused by the "thunderstorm" incident in the pharmaceutical industry came to an end.
(Medical Valley) East China Pharmaceuticals acquired a 20% stake in Swiss boric acid enterprises plus code medical beauty field layout recently, East China Pharmaceuticals announced that its wholly-owned subsidiary, Sinclair UK, invested 6 million euros to transfer a 20% stake in Kylane.
Under the terms of the equity investment agreement, Sinclair paid 6 million euros to transfer all common shares from Kylane's existing shareholders, with Sinclair holding a 20 per cent stake in Kylane after the transfer, making it its third largest shareholder.
: This transaction will further enrich the East China Pharmaceutical Medical Products Pipeline.
"Medicine Rubik's Cube" Novarce Q3 China performance increased by 13%! Sky-high cumulative global sales of gene therapy exceeded $1 billion on October 27, Novart reported net sales of $35,889 million in the first three quarters of 2020, up 4% Year-on-Year, and core operating profit of $11.915 billion, up 16% YoY.
From the 2020Q3 performance, Novarma's net sales revenue was $12,259 million, of which China's revenue was $667 million, or 4.468 billion yuan, driven by double-digit growth rates in Cosentyx and Entresto.
: Since Zolgensma's approval, cumulative sales have reached $1,027 million.
Insight Database: The third quarter sales of Xindili monoanti-resistant broke 600 million Thyme Bio2020 news continued on October 27, Xinda Bio issued an announcement to disclose dabershu (Xindili single-anti-injection) Q3 sales in 2020.
sales exceeded 600 million in the third quarter, according to the company's announcement.
based on previous Xinda disclosures, Syndication has seen quarterly sales growth since it was approved for listing in March 2019, with annual sales of 1.016 billion in 2019, Q2020 Q1 of about 400 million, Q2 of 500 million, Q3 of more than 600 million, and sales expected to stabilize by more than 2 billion in 2020.
: More than a dozen clinical trials are under way.